Biotech Biz Evozyne Closes $81M Series B Funding Round
By Jade Martinez-Pogue ( September 27, 2023, 3:52 PM EDT) -- Chicago-based biotechnology company Evozyne on Wednesday revealed that it completed its Series B funding round after raising $81 million that will be used to help fund its generative artificial intelligence-powered drug discovery platform and project development....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.